By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


 

Cyclacel Pharmaceuticals, Inc. 

200 Connell Drive
Suite 1500
Berkeley Heights  New Jersey  07922  U.S.A.
Phone: 908-517-7330 Fax: 866-271-3466


SEARCH JOBS

Cyclacel Pharmaceuticals is a biopharmaceutical company developing oral therapies that target the various phases of cell cycle control for the treatment of cancer and other serious diseases.

YEAR FOUNDED:

1996

LEADERSHIP:

Founder: Sir David Lane

CEO: Spiro Rombotis

JOBS:

Please click here for Cyclacel job opportunities.

CLINICAL TRIAL:

Please click here for clinical trial information.


Key Statistics


Email: info@cyclacel.com
Ownership: Public

Web Site: Cyclacel Pharma
Employees:
Symbol: CYCC
 









Company News
Cyclacel Pharma (CYCC) Reports Second Quarter 2017 Financial Results 8/11/2017 11:11:00 AM
Cyclacel Pharma (CYCC) Announces Selection Of Recommended Phase II Dose For CYC065 And Evidence Of Durable Target Engagement And Mcl-1 Biomarker Suppression 8/7/2017 11:11:18 AM
Cyclacel Pharma (CYCC) To Release Second Quarter 2017 Financial Results 8/2/2017 12:12:23 PM
Cyclacel Pharma (CYCC) Announces Closing Of $15.2 Million Underwritten Public Offering And Full Exercise Of Over-Allotment Option 7/24/2017 9:46:01 AM
Cyclacel Pharma (CYCC) Announces Pricing Of $13.2 Million Underwritten Public Offering 7/19/2017 8:23:25 AM
Cyclacel Pharma (CYCC) Reports First Quarter 2017 Financial Results 5/12/2017 7:48:57 AM
Cyclacel Pharma (CYCC) To Release First Quarter 2017 Financial Results 5/5/2017 8:43:52 AM
Cyclacel Pharma (CYCC) Presents Identification Of Sensitive Target Indications And Synergistic Drug Combinations For Novel PLK1 Inhibitor CYC140 4/5/2017 11:19:56 AM
Cyclacel Pharma (CYCC)'s Second-Generation CDK2/9 Inhibitor, CYC065, Elicits Marked Antineoplastic Effects In Lung Cancer By Engaging Anti-Metastatic Pathways 4/3/2017 7:35:45 AM
Cyclacel Pharma (CYCC) Reports Fourth Quarter And Full Year 2016 Financial Results 3/29/2017 9:26:39 AM
12345678910...
//-->